A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

You may not qualify if…

• ✕ 1. Participants with familial chylomicronemia syndrome (FCS). Some exceptions may apply.
• ✕ 2. Evidence of liver disease, defined as but not limited to:
• ✕ LFTS \>2 × upper limit of normal (ULN), or total bilirubin \>2 × ULN, or INR \>1.5 × ULN, or liver stiffness measured by liver elastography
• ✕ 3. Abnormal or compromised function of kidney, heart, blood or liver.
• ✕ 4. Acute coronary syndrome event or stroke within 24 weeks prior to Day 1. Acute pancreatitis within 12 weeks prior to Day 1.
• ✕ 5. Current use or use within 365 days from Day 1 of any hepatocyte-targeted small interfering RNA (except inclisiran).
• ✕ 6. Positive serology for HIV, hepatitis B or hepatitis C (antibody, surface antigen orNAT). Serology consistent with prior immunization will be eligible for the trial.
• ✕ 7. Any prior malignancy within the past 5 years, or current malignancy (exceptions for resected or removed basal cell carcinoma, squamous cell carcinoma in situ and carcinoma in situ of the cervix or breast).